April 12, 2019 07:58 AM EDTUpdated April 15, 04:36 AM
Bioregnum
R&D
Opinion

Go­ing vi­ral? J&J tries to spark a Twit­ter­storm for the lat­est da­ta on its HIV med

When you set out to make a block­buster, can a Twit­ter­storm help?

About 9 months af­ter the FDA OK’d J&J’s 4-in-1 HIV pill Sym­tuza …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times